This trial is no longer recruiting

Recruitment for this study has ended, so applications are closed. You can still read the trial details, or browse similar trials that are currently recruiting.

Not recruiting

Phase 3

TAK-279A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Sponsor:

Takeda

Code:

NCT06550076

Conditions

Plaque Psoriasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TAK-279

Study Details

Brief summary:

The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis.

All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules.

Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.

Conditions

Plaque Psoriasis

Study ID

NCT06550076

Start date

Sep 4, 2024

Status verified date

Jul, 2025

Completion date

May 7, 2026

Anticipated

Primary completion date

May 7, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Main Inclusion Criteria:

Part A:

Participant is willing and able to understand and fully comply with study procedures and requirements (including digital tools and applications), in the opinion of the investigator.
Participant has provided written informed consent and any required privacy authorization before the initiation of any study procedures.
Participant is aged 18 years or older at the time of consent.
Participant has a diagnosis of chronic plaque psoriasis for >=6 months prior to the screening visit.
Participant has stable plaque psoriasis defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis for >=6 months before screening.
Participant has moderate-to-severe plaque psoriasis as defined by a PASI score >=12 and a sPGA score >=3 at screening and Day 1.
Participant has plaque psoriasis covering >=10% of his or her total BSA at screening and Day 1.
Participant must be a candidate for phototherapy or systemic therapy.

Part B:

\- Participant has completed 52 weeks of treatment (TAK-279-3001 or Part A) or 60 weeks of treatment (TAK-279-3002), or 16 weeks of treatment (TAK-279-PsO-3004) in their parent study.

Main Exclusion Criteria

Part A:

Participant has evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary.
Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune-related disease (e.g., inflammatory bowel disease).
Participant has any clinically significant medical condition, evidence of an unstable clinical condition (e.g., cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of study results. These include but are not limited to:

1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency; splenectomy.
2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the study.
3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments.
4. Participant has a history of Class III or IV congestive heart failure as defined by New York Heart Association criteria.
5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
6. For participants with asthma, chronic obstructive pulmonary disease, or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral corticosteroids, or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1.
7. Participant has any of the following cardiovascular disease history: A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, non-acute cardiac hospitalization (e.g., pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening. Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aortocoronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll.
8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the study, in the opinion of the investigator.
9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator.
10. Participant has any lifetime history of suicidal ideation, suicidal behavior, or suicidal attempts by 1) medical history; or 2) by Columbia-Suicide Severity Rating Scale (C-SSRS) documentation at screening or by answering "yes" to Question 5 for suicidal ideation on the C-SSRS at screening; or 3) is clinically deemed to have a suicide risk by the investigator.
11. Participant has a patient health questionnaire - 8 (PHQ-8) score of 15 or above at screening.
12. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1.

Participant has received any of the following biologics or biosimilar versions within the time frame indicated or 5 half-lives, whichever is longer:

1. Antibodies to interleukin (IL) -12/-23, IL-17, or IL-23 (eg, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1.
2. Tumor necrosis factor inhibitor(s) (e.g., etanercept, adalimumab, infliximab, certolizumab) within 2 months prior to Day 1.
3. Agents that modulate integrin pathways to impact lymphocyte trafficking (e.g., natalizumab) or agents that modulate B cells or T cells (e.g., alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1.
4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1.

Participant has any previous exposure to TAK-279 (also known as NDI-034858) or other TYK2 inhibitors, including deucravacitinib, or participant participated in any study that included a TYK2 inhibitor (e.g., deucravacitinib, VTX958, GLPG3667, etc.), unless the participant has documentation of post-trial unblinding that confirms the partcipant did not receive a TYK2 inhibitor.
Participant has a known or suspected allergy to TAK-279 or any of its components.

Part B:

Participant has completed the parent study or Part A but was permanently discontinued from treatment.
Participant had evidence of significant noncompliance with study visits or study drug in the parent study or Part A, as defined in the parent study protocol or in the opinion of the investigator.
Participant has met criteria for termination from the parent study or Part A, regardless of whether or not the participant was terminated from the parent study or Part A.
Participant has developed evidence of non-plaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis) since enrollment in the parent study or Part A.
Participant has developed a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments.
Participant has received a prohibited psoriasis treatment during the parent study or Part A, whether or not that treatment was documented as a concomitant medication and is expected to continue that treatment.

Study Design

Enrollment

1950 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part A (De Novo Cohort) + Part B (Open Label Extension): TAK-279

Part A: Participants will receive TAK-279, oral tablet once daily (QD) for up to 52 weeks.

Part B: Participants who completed the treatment period of parent studies (TAK-279-3001 \[NCT06088043\], TAK-279-3002 \[NCT06108544\], or TAK-279-PsO-3004 \[NCT06973291\]) or who completed Part A will receive TAK-279, oral tablet QD for up to 156 weeks.

Interventions

TAK-279

TAK-279 oral tablet

Primary outcome measure

Part A and Part B: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) [ Time Frame: From start of the drug administration up to Week 56 (Part A) and Week 160 (Part B) ]

Central Contacts and Locations

Central contacts

Takeda Contact

+1-877-825-3327 medinfoUS@takeda.com

Locations

Total Dermatology

Recruiting

Birmingham, Alabama, United States, 35205

Contacts

Site contact

205-933-0987 jkrellmd@gmail.com

Principal Investigator:

James Krell

University of Alabama Hospital - Whitaker Clinic -

Recruiting

Birmingham, Alabama, United States, 35233-2110

Contacts

Site contact

205-502-9960 belewski@uabmc.edu

Principal Investigator:

Boni Elewski

Cahaba Dermatology Skin Health Center

Recruiting

Hoover, Alabama, United States, 35244-2111

Contacts

Site contact

205-214-7546 vlada.groysman@cahabaderm.com

Principal Investigator:

Vlada Groysman

Medical Dermatology Specialists

Recruiting

Phoenix, Arizona, United States, 85006

Contacts

Site Contact

602-354-5770 ackerman.lindsay@gmail.com

Principal Investigator:

Lindsay Ackerman

Saguaro Dermatology Associates, LLC - Probity - PPDS

Recruiting

Phoenix, Arizona, United States, 85008-3884

Contacts

Site contact

480-562-3610 dhamann@saguaroderm.com

Principal Investigator:

Dathan Hamann

Noble Clinical Research

Recruiting

Tucson, Arizona, United States, 85704

Contacts

Site contact

Dpetersen@nobleclinicalresearch.com

Principal Investigator:

Dena Petersen

Johnson Dermatology Clinic

Recruiting

Fort Smith, Arkansas, United States, 72916-6103

Contacts

Site contact

479-649-3376 drsandy@johnsondermatology.com

Principal Investigator:

Sandra Johnson

Burke Pharmaceutical Research

Recruiting

Hot Springs, Arkansas, United States, 71913-6475

Contacts

Site contact

501-620-4449 dow@burketherapeutics.com

Principal Investigator:

Dowling Stough

Zenith Research, Inc.

Recruiting

Beverly Hills, California, United States, 90212

Contacts

Site contact

213-949-6427 docstop@aol.com

Principal Investigator:

David Stoll

First OC Dermatology Research Inc.

Recruiting

Fountain Valley, California, United States, 92708

Contacts

Site contact

714-531-2966 vivian.laquer@gmail.com

Principal Investigator:

Vivian Laquer

Center for Dermatology Clinical Research

Recruiting

Fremont, California, United States, 94538

Contacts

Site contact

510-797-0140 sdhaw@yahoo.com

Principal Investigator:

Sunil Dhawan

Long Beach Research Institute

Recruiting

Long Beach, California, United States, 90805

Contacts

Site contact

562-471-3773 aduzik@longbeachresearch.com

Principal Investigator:

Ashley Duzik

Metropolis Dermatology Downtown LA - Probity - PPDS

Recruiting

Los Angeles, California, United States, 90017-5310

Contacts

Site contact

424-393-0005 james.wang@metropolisderm.com

Principal Investigator:

James Wang

UCLA University of California Los Angeles

Recruiting

Los Angeles, California, United States, 90024

Contacts

Site contact

720-848-0556 aprilarmstrong@mednet.ucla.edu

Principal Investigator:

April Armstrong

Northridge Clinical Trials

Recruiting

Northridge, California, United States, 91325-4122

Contacts

Site contact

714-375-5970 nezra@northridgetrials.com

Principal Investigator:

Navid Ezra

UC Davis Dermatology Clinic

Recruiting

Sacramento, California, United States, 95816-3370

Contacts

Site contact

916-734-6111 emaverakis@ucdavis.edu

Principal Investigator:

Emanual Maverakis

TCR Medical Corporation

Recruiting

San Diego, California, United States, 92123-1523

Contacts

Site contact

858-571-6800 nbhatia@therapeuticsresearch.com

Principal Investigator:

Neal Bhatia

University Clinical Trials

Recruiting

San Diego, California, United States, 92123

Contacts

Site contact

858-278-8470 walter@univct.com

Principal Investigator:

Walter Nahm

Dermatology Institute and Skin Care Center

Recruiting

Santa Monica, California, United States, 90404-2216

Contacts

Site contact

310-828-8887 dryamauchi@csird.com

Principal Investigator:

Paul Yamauchi

UNISON Clinical Trials (Shahram Jacobs md inc.)

Recruiting

Sherman Oaks, California, United States, 91403

Contacts

Site contact

818-981-1555 dr@sjacobsmd.com

Principal Investigator:

Shahram Jacobs

Driven Research LLC

Recruiting

Coral Gables, Florida, United States, 33134-3901

Contacts

Site contact

305-677-2275 jalonso@drivenclinicalresearch.com

Principal Investigator:

Javier Alonso-Llamazares

Revival Research Corporation - Florida - ClinEdge - PPDS

Recruiting

Doral, Florida, United States, 33122-1902

Contacts

Site contact

305-982-8892 iespinosa@revivalresearch.com

Principal Investigator:

Ivette Espinosa-Fernandez

FXM Clinical Research Ft. Lauderdale, LLC

Recruiting

Fort Lauderdale, Florida, United States, 33308-5211

Contacts

Site contact

954-368-4406 igor.chaplik@fxmresearch.com

Principal Investigator:

Igor Chaplik

Direct Helpers Medical Center

Recruiting

Hialeah, Florida, United States, 33012

Contacts

Site Contact

305-324-2110 Don@dhrtrials.com

Principal Investigator:

Frank Don

Florida Academic Centers Research

Recruiting

Miami, Florida, United States, 33136-1003

Contacts

Site contact

888-888-8888 kerdel.research@fadcresearch.com

Principal Investigator:

Francisco Kerdel

FXM Clinical Research Miami, LLC

Recruiting

Miami, Florida, United States, 33175-3582

Contacts

Site contact

305-220-5222 hector.wiltz@fxmresearch.com

Principal Investigator:

Hector Wiltz

San Marcus Research Clinic Inc

Recruiting

Miami Lakes, Florida, United States, 33014

Contacts

Site contact

iacosta@sanmarcusrc.com

Principal Investigator:

Idalia Acosta

FXM Research Miramar

Recruiting

Miramar, Florida, United States, 33027-4714

Contacts

Site contact

954-430-1097 francisco.flores@fxmresearch.com

Principal Investigator:

Francisco Flores

Renstar Medical Research -21 NE 1st Ave

Recruiting

Ocala, Florida, United States, 34470

Contacts

Site contact

352-629-5800 ashley.cauthen@renstar.net

Principal Investigator:

Ashley Cauthen

Lenus Research & Medical Group

Recruiting

Sweetwater, Florida, United States, 33172

Contacts

Site contact

305-592-4692 jniven@lenusresearch.com

Principal Investigator:

John Niven

Advanced Clinical Research Institute (ACRI) - Florida

Recruiting

Tampa, Florida, United States, 33607-6429

Contacts

Site contact

813-879-7546 drcaban@acrinstitute.com

Principal Investigator:

Francis Caban

Divine Dermatology and Aesthetics, LLC

Recruiting

Atlanta, Georgia, United States, 30315-2042

Contacts

Site contact

470-747-7888 dr.c@divinedermatl.com

Principal Investigator:

Tunisia Cornelius

Marietta Dermatology & The Skin Cancer Center - Marietta

Recruiting

Marietta, Georgia, United States, 30060-7902

Contacts

Site contact

770-421-2037 mknautz@mariettaderm.com

Principal Investigator:

Mark Knautz

Advanced Medical Research, PC

Recruiting

Sandy Springs, Georgia, United States, 30328

Contacts

Site contact

404-939-9220 jweisman8943@atlmedderm.com

Principal Investigator:

Jamie Weisman

Georgia Skin and Cancer Clinic

Recruiting

Savannah, Georgia, United States, 31419-1768

Contacts

Site contact

919-830-4841 ssmith@georgiaskinandcancer.com

Principal Investigator:

Sidney Smith

Leavitt Clinical Research

Recruiting

Idaho Falls, Idaho, United States, 83404-8322

Contacts

Site contact

208-502-3039 drminer@highvalleydermatology.com

Principal Investigator:

Brandon Miner

Arlington Dermatology

Recruiting

Rolling Meadows, Illinois, United States, 60008-3811

Contacts

Site contact

847-392-5440 bukhalom@hotmail.com

Principal Investigator:

Michael Bukhalo

NorthShore Medical Group Dermatology - Skokie

Recruiting

Skokie, Illinois, United States, 60077-1049

Contacts

Site contact

847-663-6813 smehlis@northshore.org

Principal Investigator:

Stephanie Mehlis

DS Research - 1005 E. Lewis & Clark Pkwy Indiana Location

Recruiting

Clarksville, Indiana, United States, 47129-2201

Contacts

Site contact

502-373-2849 mvissing@dsresearch.com

Principal Investigator:

Megan Vissing

Dawes Fretzin Clinical Research Group, LLC

Recruiting

Indianapolis, Indiana, United States, 46250

Contacts

Site contact

317-516-5030 kdawes@ecommunity.com

Principal Investigator:

Kenneth Dawes

Skin Sciences, PLLC

Recruiting

Louisville, Kentucky, United States, 40217-1444

Contacts

Site contact

502-456-2783 wedoderm@yahoo.com

Principal Investigator:

Leon Kircik

Dermatology Specialists Research - 3810 Springhurst Blvd

Recruiting

Louisville, Kentucky, United States, 40241-6162

Contacts

Site contact

502-585-9059 cowen@dsrtrials.com

Principal Investigator:

Cindy Owen

Lawrence J Green, MD LLC

Recruiting

Rockville, Maryland, United States, 20850

Contacts

Site contact

301-610-0663 drgreen@aederm.com

Principal Investigator:

Lawrence Green

University of Michigan Hospital - 1500 E Medical Center Dr

Recruiting

Ann Arbor, Michigan, United States, 48109-5360

Contacts

Site contact

734-936-4075 goldfrb@umich.edu

Principal Investigator:

Michael Goldfarb

Oakland Hills Dermatology - 3400 Auburn Rd

Recruiting

Auburn Hills, Michigan, United States, 48326-3396

Contacts

Site contact

833-254-6829 buattichris@yahoo.com

Principal Investigator:

Christofer Buatti

Revival Research Corporation - ClinEdge

Recruiting

Troy, Michigan, United States, 48084-3536

Contacts

Site contact

248-564-1485 amoiin@rev-research.com

Principal Investigator:

Ali Moiin

Minnesota Clinical Study Center

Recruiting

New Brighton, Minnesota, United States, 55112

Contacts

Site contact

763-571-4200 sekempers@gmail.com

Principal Investigator:

Steven Kempers

Skin Specialists PC

Recruiting

Omaha, Nebraska, United States, 68144

Contacts

Site contact

skindoc@lovelyskin.com

Principal Investigator:

Joel Schlessinger

Henderson Clinical Trials

Recruiting

Henderson, Nevada, United States, 89052

Contacts

Site contact

725-218-3236 vsayal@hendersontrials.com

Principal Investigator:

Vikas Sayal

Dartmouth Hitchcock Medical Center - Old Etna Rd

Recruiting

Lebanon, New Hampshire, United States, 03766-1937

Contacts

Site contact

603-650-3108 brian.j.simmons@hitchcock.org

Principal Investigator:

Brian Simmons

ALLCUTIS Research, LLC.

Recruiting

Portsmouth, New Hampshire, United States, 03801

Contacts

Site contact

603-319-8863 ajarell@activmedresearch.com

Principal Investigator:

Abel Jarell

Psoriasis Treatment Center of Central New Jersey

Recruiting

East Windsor, New Jersey, United States, 08520

Contacts

Site contact

609-443-4500 dreamacres1@aol.com

Principal Investigator:

Jerry Bagel

Sadick Research Group

Recruiting

New York, New York, United States, 10075-0385

Contacts

Site contact

212-772-7242 nssderm@sadickdermatology.com

Principal Investigator:

Neil Sadick

Montefiore AOA - BRANY

Recruiting

The Bronx, New York, United States, 10467

Contacts

Site contact

718-920-8352 hkanavy@montefiore.org

Principal Investigator:

Holly Kanavy

Accellacare of Cary

Recruiting

Cary, North Carolina, United States, 27518

Contacts

Site contact

919-342-3447 cathyhren@gmail.com

Principal Investigator:

Catherine Hren

The Skin Surgery Center for Clinical Research - Objective Health - PPDS

Recruiting

Winston-Salem, North Carolina, United States, 27103-7109

Contacts

Site contact

336-200-8208 kevin.stein@objective.health

Principal Investigator:

Kevin Stein

Bexley Dermatology Research - Probity - PPDS

Recruiting

Bexley, Ohio, United States, 43209

Contacts

Site contact

614-293-4464 matt.zirwas@gmail.com

Principal Investigator:

Matthew Zirwas

Wright State Physicians

Recruiting

Fairborn, Ohio, United States, 45324

Contacts

Site contact

937-245-7500 craig.rohan@wright.edu

Principal Investigator:

Craig Rohan

Apex Clinical Research Center

Recruiting

Mayfield Heights, Ohio, United States, 44124-4005

Contacts

Site contact

440-352-7546 jgarcia@apexskin.com

Principal Investigator:

Jorge Garcia-Zuazaga

Oregon Medical Research Center PC

Recruiting

Portland, Oregon, United States, 97201

Contacts

Site contact

503-245-1525 behst@oregonmedicalresearch.com

Principal Investigator:

Benjamin Ehst

University of Pittsburgh Medical Center-3601 5th Ave

Recruiting

Pittsburgh, Pennsylvania, United States, 15213-3403

Contacts

Site contact

412-647-2013 ferrislk@upmc.edu

Principal Investigator:

Laura Ferris

Cumberland Skin Center for Clinical Research - Objective Health - PPDS

Recruiting

Hermitage, Tennessee, United States, 37076-3497

Contacts

Site contact

615-829-6980 judy.hu@objective.health

Principal Investigator:

Judy Hu

International Clinical Research US LLC

Recruiting

Murfreesboro, Tennessee, United States, 37130-2450

Contacts

Site contact

cfeser@icresearch.net

Principal Investigator:

Christina Feser

Arlington Research Center

Recruiting

Arlington, Texas, United States, 76011-3800

Contacts

Site contact

817-795-7546 acderm@acderm.com

Principal Investigator:

Angela Moore

Bellaire Dermatology Associates

Recruiting

Bellaire, Texas, United States, 77401-3505

Contacts

Site contact

713-661-4383 cteller@bellairedermatology.com

Principal Investigator:

Craig Teller

UT Physicians Dermatology - Bellaire Station

Recruiting

Bellaire, Texas, United States, 77401

Contacts

Site contact

adelaide.a.hebert@uth.tmc.edu

Principal Investigator:

Adelaide Hebert

Modern Research Associates

Recruiting

Dallas, Texas, United States, 75231-6077

Contacts

Site contact

214-265-1818 drcather@mradallas.com

Principal Investigator:

Jennifer Cather

North Texas Center for Clinical Research

Recruiting

Frisco, Texas, United States, 75034

Contacts

Site contact

972-704-2400 trodgers@rodgersderm.com

Principal Investigator:

Timothy Rodgers

San Antonio

Recruiting

San Antonio, Texas, United States, 78213-2250

Contacts

Site contact

210-614-5557 drlee@progclin.com

Principal Investigator:

Mark Lee

Texas Dermatology and Laser Specialists-San Antonio-7703 Floyd Curl Dr

Recruiting

San Antonio, Texas, United States, 78218-3128

Contacts

Site contact

210-852-2779 drbrowning@texasdls.com

Principal Investigator:

John Browning

Dermatology Clinical Research Center of San Antonio

Recruiting

San Antonio, Texas, United States, 78229-3409

Contacts

Site contact

210-692-1382 drdavis@dermresearchsa.com

Principal Investigator:

Steven Davis

Houston Center for Clinical Research, LLC

Recruiting

Sugar Land, Texas, United States, 77479-1001

Contacts

Site contact

832-929-6221 atamirisa@houstonclinicalresearch.com

Principal Investigator:

Aparna Tamirisa

Center For Clinical Studies, LTD. LLP - 451 N Texas Ave

Recruiting

Webster, Texas, United States, 77598-4927

Contacts

Site contact

281-333-2288 plee@ccstexas.com

Principal Investigator:

Patricia Lee

Virginia Clinical Research - 6160 Kempsville Cir

Recruiting

Norfolk, Virginia, United States, 23507

Contacts

Site contact

757-625-0151 dpariser@pariserderm.com

Principal Investigator:

David Pariser

Beacon Dermatology - Probity

Recruiting

Calgary, Alberta, Canada, T3A 2N1

Contacts

Site contact

(587) 392-7546 andrei.metelitsa@gmail.com

Principal Investigator:

Andrei Metelitsa

Dermatology Research Institute, Inc.

Recruiting

Calgary, Alberta, Canada, T3A 2N1

Contacts

Site contact

(403) 284-4222 vimal@dermatologyresearch.ca

Principal Investigator:

Vimal Prajapati

Alberta DermaSurgery Centre - Probity

Recruiting

Edmonton, Alberta, Canada, T6G 1C2

Contacts

Site contact

(780) 437-7189 jrao@raoderm.com

Principal Investigator:

Jaggi Rao

VIDA Dermatology - Probity

Recruiting

Edmonton, Alberta, Canada, T6H 4J8

Contacts

Site contact

(780) 760-8432 drkurian@vidadermatology.com

Principal Investigator:

Anil Kurian

Care Clinic

Recruiting

Red Deer, Alberta, Canada, T4P 1K4

Contacts

Site contact

(587) 273-4773 isaiah@careclinicrd.ca

Principal Investigator:

Isaiah Day

Enverus Medical Research - Probity

Recruiting

Surrey, British Columbia, Canada, V3V 0C6

Contacts

Site contact

(604) 495-8278 lalbrecht@enverusmedical.com

Principal Investigator:

Lorne Albrecht

Wiseman Dermatology Research Inc.

Recruiting

Winnipeg, Manitoba, Canada, R3E 0V9

Contacts

Site contact

(204) 294-2941 mwiseman@skinwise.ca

Principal Investigator:

Marni Wiseman

Karma Clinical Trials

Recruiting

St. John's, Newfoundland and Labrador, Canada, A1A 4Y3

Contacts

Site contact

(709) 739-9733 kohson@mun.ca

Principal Investigator:

Kamal Ohson

CCA Medical Research - Probity

Recruiting

Ajax, Ontario, Canada, L1S 7K8

Contacts

Site contact

(905) 427-3996 dnadam@ccamedicalresearch.com

Principal Investigator:

David Adam

SimcoDerm Medical and Surgical Dermatology Centre - Probity

Recruiting

Barrie, Ontario, Canada, L4M 7G1

Contacts

Site Contact

(705) 503-6333 derm@simcoderm.com

Principal Investigator:

Maryam Shayesteh Alam

Kingsway Clinical Research - Probity

Recruiting

Etobicoke, Ontario, Canada, M8X 1Y9

Contacts

Site contact

(416) 231-0100 epoulos@yahoo.com

Principal Investigator:

Elena Poulos

Guelph Dermatology Research - Probity

Recruiting

Guelph, Ontario, Canada, N1L 0B7

Contacts

Site contact

(519) 836-7345 guelphdermrxd@gmail.com

Principal Investigator:

Dusan Sajic

Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity

Recruiting

Hamilton, Ontario, Canada, L8L 3C3

Contacts

Site contact

(519) 579-9535 leader@leaderresearch.ca

Principal Investigator:

Jose Hermenio Cavalcante Lima Filho

Dermatrials Research

Recruiting

Hamilton, Ontario, Canada, L8N 1Y2

Contacts

Site contact

(905) 962-3376 ron.vender@me.com

Principal Investigator:

Ronald Vender

Mediprobe Research Inc

Recruiting

London, Ontario, Canada, N5X 2P1

Contacts

Site contact

(888) 888-8888 agupta@mediproberesearch.com

Principal Investigator:

Aditya Gupta

DermEffects

Recruiting

London, Ontario, Canada, N6H 5L5

Contacts

Site contact

(519) 204-6868 dermeffects@gmail.com

Principal Investigator:

Wei Jing Loo

Lynderm Research Inc - Probity

Recruiting

Markham, Ontario, Canada, L3P 1X3

Contacts

Site contact

(905) 471-8011 derma@lynderma.com

Principal Investigator:

Charles Lynde

DermEdge Research - Probity

Recruiting

Mississauga, Ontario, Canada, L5H 1G9

Contacts

Site contact

(905) 274-9999 drlomaga@dermedge.com

Principal Investigator:

Mark Lomaga

Dr. S. K. Siddha Medicine Professional Corporation | Newmarket, Canada

Recruiting

Newmarket, Ontario, Canada

Contacts

Site contact

(905) 883-7997 siddhasanjay@hotmail.com

Principal Investigator:

Sanjay Siddha

North Bay Dermatology Center - Probity

Recruiting

North Bay, Ontario, Canada, P1B 3Z7

Contacts

Site contact

(705) 476-4539 lesrosoph@gmail.com

Principal Investigator:

Leslie Rosoph

The Centre for Clinical Trials Inc.

Recruiting

Oakville, Ontario, Canada, L6J 7W5

Contacts

Site contact

(888) 888-8888 drsapra@icls.ca

Principal Investigator:

Sheetal Sapra

Skin Centre for Dermatology

Recruiting

Peterborough, Ontario, Canada, K9J 5K2

Contacts

Site contact

(289) 252-1856 mgooderham@centrefordermatology.com

Principal Investigator:

Melinda Gooderham

The Centre For Dermatology

Recruiting

Richmond Hill, Ontario, Canada, L4B 1A5

Contacts

Site contact

(905) 889-2005 maniraman@tcfd.ca

Principal Investigator:

Mani Raman

North York Research Inc. - Probity

Recruiting

Toronto, Ontario, Canada, M2N 3A6

Contacts

Site contact

(416) 222-7546 niakosari@bnderm.com

Principal Investigator:

Firouzeh Niakosari

Canadian Dermatology Centre - Probity

Recruiting

Toronto, Ontario, Canada, M3B 0A7

Contacts

Site contact

(416) 244-8377 drahluwalia@canadiandermatology.com

Principal Investigator:

Renita Ahluwalia

Toronto Research Centre

Recruiting

Toronto, Ontario, Canada, M3H 5Y8

Contacts

Site contact

(416) 633-0001 maxwell.sauder@medportal.ca

Principal Investigator:

Maxwell Sauder

Toronto Research Centre - Probity

Recruiting

Toronto, Ontario, Canada, M4W 2N4

Contacts

Site contact

(416) 962-0123 sh@dermonbloor.com

Principal Investigator:

Sameh Hanna

Alliance Clinical Trials

Recruiting

Waterloo, Ontario, Canada, N2J 1C4

Contacts

Site contact

(519) 579-9535 kapapp@actrials.ca

Principal Investigator:

Kim Papp

XLR8 Medical Research

Recruiting

Windsor, Ontario, Canada, N8T 1E6

Contacts

Site contact

(519) 971-9700 dtoth@jet2.net

Principal Investigator:

Darryl Toth

Siena Medical Research Corporation

Recruiting

Montreal, Quebec, Canada, H3Z 2S6

Contacts

Site contact

(514) 788-3203 wayne.carey@mcgill.ca

Principal Investigator:

Wayne Carey

Skinsense Medical Research - Probity

Recruiting

Saskatoon, Saskatchewan, Canada, S7K 0H6

Contacts

Site Contact

(306) 664-7546 walkerka@dal.ca

Principal Investigator:

Kirsten Walker

More Information

Sponsor

Takeda

Last update posted

Aug 6, 2025

Last verified

Jul, 2025

Keywords

Latitude Psoriasis 3
Latitude Research Program
Latitude PsO OLE

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-16. This information was provided to ClinicalTrials.gov by Takeda on 2025-08-06.